Losartan and Emotional Learning
ConditionEmotional Processing
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-50
SponsorUniversity of Oxford
About this trial
This study explores the effects of single-dose losartan (50mg) versus placebo on emotional processing in healthy volunteers.
Eligibility criteria
Qualifiers
Willing and able to provide informed consent
Aged 18-50 years
Score of or below 45 on the Dimensional Anhedonia Rating Scale (DARS; Rizvi et al., 2015)
Sufficient written and spoken English skills to understand what the study involves, and to complete the questionnaires
Disqualifiers
Past or present DSM-5 axis-I diagnosis (based on SCID results at screening) other than anxiety disorder, dysthymia or unipolar depression
First-degree family member with severe psychiatric illness
CNS-medication last 6 weeks (including as part of another study)
Current blood pressure or other heart medication (especially aliskiren or beta blockers)
Trial design
Treatments tested in this trial
- Losartan potassium 50mg
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Oxford
Lead sponsor
National Institute for Health Research, United Kingdom
Collaborator
Source ClinicalTrials.gov